


Herausforderungen in der Behandlung des Pankreaskarzinoms



Kontakt: cwestpha@med.lmu.de

FOOTPATH

A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH)

[NCT03487016](#)


Studienleitung: Professor Dr. V. Heinemann (LMU München)

Studienkoordination: Dr. B. Westphalen (LMU München)

[Link: NCT03487016](#)

Kontakt: cwestpha@med.lmu.de

Studiensetup



[Link: NCT03487016](https://clinicaltrials.gov/ct2/show/study/NCT03487016)

Kontakt: cwestpha@med.lmu.de

- **270 Patienten (90/Arm)**
- **Interim Analyse für “futility” (B & C) n. 45 Patienten**
- **Primärer Endpunkt (Phase II): PFS**
- **Aktuell 40 Zentren (Phase II)**

[Link: NCT03487016](https://clinicaltrials.gov/ct2/show/study/NCT03487016)

Kontakt: cwestpha@med.lmu.de



PROJECTION

PROJECTION

Prognostic role of circulating tumor DNA in resectable pancreatic cancer

[NCT04246203](#)

Studienleitung: Dr. B. Westphalen (LMU München)

Studienkoordination: Professor Dr. V. Heinemann (LMU München)


[Link: NCT04246203](#)

Kontakt: cwestpha@med.lmu.de



PROJECTION

Studiensetup



Link: [NCT04246203](https://clinicaltrials.gov/ct2/show/study/NCT04246203)

Kontakt: cwestpha@med.lmu.de